Apollon Wealth Management LLC Acquires 5,572 Shares of Johnson & Johnson (NYSE:JNJ)

Apollon Wealth Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 111,072 shares of the company's stock after acquiring an additional 5,572 shares during the quarter. Apollon Wealth Management LLC's holdings in Johnson & Johnson were worth $18,420,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. MRP Capital Investments LLC grew its stake in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares during the last quarter. Syverson Strege & Co lifted its holdings in shares of Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after buying an additional 65 shares during the period. MBA Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the period. Sovereign Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc lifted its holdings in shares of Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the period. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Morgan Stanley restated an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday, July 10th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $1.44 during trading hours on Tuesday, reaching $155.38. The stock had a trading volume of 6,860,493 shares, compared to its average volume of 8,081,538. The firm has a market capitalization of $373.86 billion, a PE ratio of 17.28, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm has a 50-day simple moving average of $153.79 and a 200-day simple moving average of $154.63. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.